Salesforce to launch Vaccine Cloud to better manage COVID-19 vaccinations
Published 3 February 2021
US-based cloud computing major Salesforce has announced that it will be launching a Vaccine Cloud to help governments and healthcare institutions better manage COVID-19 vaccinations.
Operating via an end-to-end management platform, governments, healthcare providers, and organisations are able to plan, manage, and track vaccination efforts at scale, the company said.
From recipient registration, to inventory management, to monitoring of post-vaccination results, Vaccine Cloud is able to provide better support to vaccination programmes, it added. When globally, COVID-19 had reached its peak in March last year, Salesforce came up with a COVID-19 Response Package — a solution that can be deployed quickly and at no charge for six months.
This solution granted free access to technology for emergency response teams, call centers and care management teams for health systems affected by coronavirus. It included a Pre-Configured Health Cloud Org- to help manage increased volume of health-related requests via phone and chat with an emergency response contact center solution.
Further, it included the privacy and security of data to meet internal and external compliance requirements like HIPAA in the US. Powered by Salesforce Shield, a personalized, self-service resource center to help inform HCPs, patients, members and communities and help offset the higher call volumes and a learning platform to quickly distribute the latest safety and testing protocols to enable staff and ensure certification through an on-demand, learning platform.
“The biggest challenge the world faces right now is orchestrating the distribution of billions of vaccine doses. Technology can play a critical role,” said Salesforce President and COO, Bret Taylor.
The company revealed that as of now, partners that are on board the Vaccine Cloud include global consulting firms Accenture, Deloitte, and KPMG.
The race to vaccinate the world
COVID-19 vaccines from Pfizer and Moderna have been administered for emergency use in the US, having efficacy rates of 95 per cent and 94.1 per cent respectively when it comes to preventing the illness. At the time of writing, the Joe Biden administration has announced the purchase of 200 million more doses to vaccinate the American population.
In Southeast Asia, Singapore became the first country to start its vaccination program, administering Pfizer and BioNTech to frontline healthcare workers at the end of December last year.